SYBX Nasdaq

Synlogic, Inc.

SYBX | $1.815 -0.82% -0.83% 54K

(0.0% 1d) (6.9% 1m) (188.4% 1y) (0.0% 2d) (5.6% 3d) (3.9% 7d) (35.81% volume)
Earnings Calendar: 2024-03-27
Market Cap: $ 21,139,263
http://www.synlogictx.com
Sec Filling | Patents | 76 employees

(US) Synlogic, Inc. is a clinical-stage biopharmaceutical company. It engages in drug discovery and development of synthetic biotic medicines. The firm focuses on SYNB1020 and SYNB1618, which are orally administered and target hyperammonemia and phenylketonuria. It also works on SYNB1891, an intratumorally administered which treats cancer. The company was founded by Jim Collins and Tim Lu on August 28, 2017, and is headquartered in Cambridge, MA.

cancer drug discovery

add to watch list Paper trade email alert is off

Press-releases

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -1.58% | O: -1.58% H: 9.09% C: -4.81%
year financial results

Synlogic Adopts Limited Duration Stockholders Rights Plan
Published: 2024-02-20 (Crawled : 17:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| 3.6% | O: -3.05% H: 5.14% C: 5.14%

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
Published: 2024-02-08 (Crawled : 21:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -45.8% | O: -53.33% H: 14.29% C: 9.94%
update study

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
Published: 2024-02-02 (Crawled : 17:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -46.42% | O: -0.29% H: 4.02% C: -2.01%
synb1353 publication treatment preclinical potential

Synlogic Provides Corporate Update and Outlook for 2024
Published: 2024-01-04 (Crawled : 12:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -60.88% | O: 0.0% H: 3.56% C: -4.6%
update

Synlogic Announces Contract with the Air Force Research Lab
Published: 2023-12-27 (Crawled : 12:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -51.68% | O: 0.78% H: 0.56% C: -7.95%
air contract research

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
Published: 2023-12-07 (Crawled : 12:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -26.67% | O: 0.2% H: 14.68% C: 11.38%
conference presentation international

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-09 (Crawled : 12:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -12.21% | O: 0.0% H: 9.0% C: -15.02%
update financial results

Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
Published: 2023-11-07 (Crawled : 12:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -12.62% | O: -1.4% H: 9.24% C: -1.9%
payment research collaboration roche milestone

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
Published: 2023-10-03 (Crawled : 20:00) - globenewswire.com
SYBX | $1.815 -0.82% -0.83% 54K

Health Technology

| -28.9% | O: 0.0% H: 16.73% C: 10.65%
offering

See all